{"id":952444,"date":"2026-04-17T07:04:13","date_gmt":"2026-04-17T11:04:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/"},"modified":"2026-04-17T07:04:13","modified_gmt":"2026-04-17T11:04:13","slug":"upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/","title":{"rendered":"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WALTHAM, Mass., April  17, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bu3pt0gtafbHuvYXnkfprCTCFtb7pvCt4sMw3T-8Xe4FUU7oWpMugdCFWsbd920dqlpJb7QEGjmeUJSl7km62whxqnGR2FjYLwxKdJvX1QI=\" rel=\"nofollow\" target=\"_blank\">Upstream Bio, Inc.<\/a>\u00a0 (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers.<\/p>\n<p>\n        <strong>Presentation details:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Presentation Title: <\/strong>Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, Administered in Participants with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma in the VIBRANT Trial<br \/><strong>Presenting Author: <\/strong>Joseph K. Han, MD, Old Dominion University<br \/><strong>Poster Board Number: <\/strong>P1397<br \/><strong>Session: <\/strong>B32 \u2013 Rise of the Biologics: A New Hope for Breathing Easier<br \/><strong>Presentation Date and Time: <\/strong>Monday, May 18, 2026 \u2013 11:30 AM \u2013 1:15 PM ET<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Presentation Title: <\/strong>Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, in Chronic Rhinosinusitis with Nasal Polyps: Effect on Type 2 Inflammatory Biomarkers in the VIBRANT Trial<br \/><strong>Presenting Author: <\/strong>Joseph K. Han, MD, Old Dominion University<br \/><strong>Poster Board Number: <\/strong>P1398<br \/><strong>Session: <\/strong>B32 \u2013 Rise of the Biologics: A New Hope for Breathing Easier<br \/><strong>Presentation Date and Time: <\/strong>Monday, May 18, 2026 \u2013 11:30 AM \u2013 1:15 PM ET<\/li>\n<\/ul>\n<p>\n        <strong>About Upstream Bio<\/strong><br \/>\n        <br \/>Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio\u2019s team is committed to maximizing verekitug\u2019s unique attributes to address the substantial unmet needs for patients underserved by today\u2019s standard of care. To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=svYRyda1r533SeFTNkwxV2S6msprNtLY5a3C_gO6dhLyeoPm-_A3TDkClDr0MEzlA7-YJTZqh6lEeo834vetix7KzYawoSXa1OHOhDTxSJM=\" rel=\"nofollow\" target=\"_blank\">www.upstreambio.com<\/a>.<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong><br \/>\n        <br \/>Meggan Buckwell<br \/>Director, Corporate Communications and Investor Relations<br \/>ir@upstreambio.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDc0ZjRhZTYtZDFhYS00ZTg5LThiYmMtNTk4ZDIxZWE0MTgwLTEzMDQyOTEtMjAyNi0wNC0xNy1lbg==\/tiny\/Upstream-Bio.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) &#8212; Upstream Bio, Inc.\u00a0 (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers. Presentation details: Presentation Title: Verekitug, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952444","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) &#8212; Upstream Bio, Inc.\u00a0 (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers. Presentation details: Presentation Title: Verekitug, &hellip; Continue reading &quot;Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T11:04:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference\",\"datePublished\":\"2026-04-17T11:04:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/\"},\"wordCount\":395,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/\",\"name\":\"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=\",\"datePublished\":\"2026-04-17T11:04:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/","og_locale":"en_US","og_type":"article","og_title":"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Market Newsdesk","og_description":"WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) &#8212; Upstream Bio, Inc.\u00a0 (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers. Presentation details: Presentation Title: Verekitug, &hellip; Continue reading \"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T11:04:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference","datePublished":"2026-04-17T11:04:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/"},"wordCount":395,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/","name":"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=","datePublished":"2026-04-17T11:04:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTg1NSM3NTQxMDc4IzIyOTI3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952444"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952444\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}